LENZ Therapeutics, Inc. - Common Stock (LENZ)

LENZ Therapeutics (NASDAQ:LENZ) reported first-quarter 2026 results that showed continued prescription growth for its presbyopia eye drop VIZZ, while management acknowledged that new patient adoption and routine prescribing by eye care professionals are developing more gradually than expected. Pres

Lenz (LENZ) Q1 2026 Earnings Call Transcript

It failed to meet expectations for its final quarter of 2025.

Is it time to throw away your reading glasses? Maybe not just yet.

LENZ Therapeutics (NASDAQ:LENZ) to release Q4 earnings on 3/24. Analysts expect loss of 90 cents/share. Stock gained 5% on Monday. Analyst ratings and accuracy rates available on Benzinga.

LENZ Therapeutics Q3 2025 results show an 80% revenue beat and narrower loss as it launches its new FDA-approved vision treatment, VIZZ™.

San Diego, CA – September 27, 2025 – LENZ Therapeutics (NASDAQ: LENZ) is facing heightened scrutiny this week following a significant insider share sale by a major shareholder, Versant Venture Capital VI, L.P., and its affiliated entities. The coordinated disposition of over 135,000 shares, valued at more than $5.7

LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025.

LENZ Therapeutics and Corxel Pharmaceuticals announced Phase 3 data for LNZ100, showing significant presbyopia improvements, supporting potential FDA approval.

Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug application.

LENZ stock results show that LENZ Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.